Gp-100 as a Novel Therapeutic Target in Uveal Melanoma
Uveal melanoma is a rare neoplasm with poor prognosis in the metastatic setting. Unlike cutaneous melanoma, treatment with kinase inhibitors or immune checkpoint inhibitors is not effective. Glycoprotein 100 (Gp-100) is a protein highly expressed in melanocytes and melanoma that has recently been ef...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2021-11-01
|
| Series: | Cancers |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2072-6694/13/23/5968 |
| _version_ | 1797507975107051520 |
|---|---|
| author | Daniel Martinez-Perez David Viñal Isabel Solares Enrique Espinosa Jaime Feliu |
| author_facet | Daniel Martinez-Perez David Viñal Isabel Solares Enrique Espinosa Jaime Feliu |
| author_sort | Daniel Martinez-Perez |
| collection | DOAJ |
| description | Uveal melanoma is a rare neoplasm with poor prognosis in the metastatic setting. Unlike cutaneous melanoma, treatment with kinase inhibitors or immune checkpoint inhibitors is not effective. Glycoprotein 100 (Gp-100) is a protein highly expressed in melanocytes and melanoma that has recently been effectively targeted by tebentafusp, a first-in-class bispecific protein of the immune-mobilizing monoclonal T cell receptors against cancer (ImmTACs) family. Tebentafusp targets tumor cells that express a peptide of Gp-100 presented by HLA*A0201, creating an immune synapse that kills targeted tumor cells. Recently, a randomized phase III trial reported an overall survival benefit for tebentafusp in patients with untreated metastatic uveal melanoma. The aim of this comprehensive review is to summarize evidence of Gp-100 as a therapeutic target in melanoma, and the preclinical and clinical development of tebentafusp as a novel therapeutic strategy for patients with uveal melanoma. |
| first_indexed | 2024-03-10T04:56:02Z |
| format | Article |
| id | doaj.art-40784dd372de4f83b818ff86adf93e7a |
| institution | Directory Open Access Journal |
| issn | 2072-6694 |
| language | English |
| last_indexed | 2024-03-10T04:56:02Z |
| publishDate | 2021-11-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cancers |
| spelling | doaj.art-40784dd372de4f83b818ff86adf93e7a2023-11-23T02:12:20ZengMDPI AGCancers2072-66942021-11-011323596810.3390/cancers13235968Gp-100 as a Novel Therapeutic Target in Uveal MelanomaDaniel Martinez-Perez0David Viñal1Isabel Solares2Enrique Espinosa3Jaime Feliu4Department of Medical Oncology, Hospital Universitario La Paz, Paseo de la Castellana 261, 28046 Madrid, SpainDepartment of Medical Oncology, Hospital Universitario La Paz, Paseo de la Castellana 261, 28046 Madrid, SpainDepartment of Internal Medicine, Hospital Universitario 12 de Octubre, 28041 Madrid, SpainDepartment of Medical Oncology, Hospital Universitario La Paz, IdiPAZ, Catedra UAM-AMGEN, Centro de Investigación Biomédica en Red Cáncer (CIBERONC), 28046 Madrid, SpainDepartment of Medical Oncology, Hospital Universitario La Paz, IdiPAZ, Catedra UAM-AMGEN, Centro de Investigación Biomédica en Red Cáncer (CIBERONC), 28046 Madrid, SpainUveal melanoma is a rare neoplasm with poor prognosis in the metastatic setting. Unlike cutaneous melanoma, treatment with kinase inhibitors or immune checkpoint inhibitors is not effective. Glycoprotein 100 (Gp-100) is a protein highly expressed in melanocytes and melanoma that has recently been effectively targeted by tebentafusp, a first-in-class bispecific protein of the immune-mobilizing monoclonal T cell receptors against cancer (ImmTACs) family. Tebentafusp targets tumor cells that express a peptide of Gp-100 presented by HLA*A0201, creating an immune synapse that kills targeted tumor cells. Recently, a randomized phase III trial reported an overall survival benefit for tebentafusp in patients with untreated metastatic uveal melanoma. The aim of this comprehensive review is to summarize evidence of Gp-100 as a therapeutic target in melanoma, and the preclinical and clinical development of tebentafusp as a novel therapeutic strategy for patients with uveal melanoma.https://www.mdpi.com/2072-6694/13/23/5968uveal melanomatebentafuspglycoprotein 100 |
| spellingShingle | Daniel Martinez-Perez David Viñal Isabel Solares Enrique Espinosa Jaime Feliu Gp-100 as a Novel Therapeutic Target in Uveal Melanoma Cancers uveal melanoma tebentafusp glycoprotein 100 |
| title | Gp-100 as a Novel Therapeutic Target in Uveal Melanoma |
| title_full | Gp-100 as a Novel Therapeutic Target in Uveal Melanoma |
| title_fullStr | Gp-100 as a Novel Therapeutic Target in Uveal Melanoma |
| title_full_unstemmed | Gp-100 as a Novel Therapeutic Target in Uveal Melanoma |
| title_short | Gp-100 as a Novel Therapeutic Target in Uveal Melanoma |
| title_sort | gp 100 as a novel therapeutic target in uveal melanoma |
| topic | uveal melanoma tebentafusp glycoprotein 100 |
| url | https://www.mdpi.com/2072-6694/13/23/5968 |
| work_keys_str_mv | AT danielmartinezperez gp100asanoveltherapeutictargetinuvealmelanoma AT davidvinal gp100asanoveltherapeutictargetinuvealmelanoma AT isabelsolares gp100asanoveltherapeutictargetinuvealmelanoma AT enriqueespinosa gp100asanoveltherapeutictargetinuvealmelanoma AT jaimefeliu gp100asanoveltherapeutictargetinuvealmelanoma |